Zhitong Finance App News, Lianhuan Pharmaceutical (600513.SH) issued an announcement. Recently, the company received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for the active ingredient agatroban issued by the State Drug Administration. Agatripan is a direct thrombin inhibitor that reversibly binds to thrombin active sites. Its injections are suitable for: (1) improving neurological symptoms (motor paralysis) and daily activities (walking, standing, sitting, eating) in patients with acute ischemic stroke within 48 hours of onset; (2) improving limb ulcers, resting pain, and cold sensation in patients with chronic arterial occlusion (thromboangiitis obliterans, arteriosclerosis obliterans).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.